Shots:
- The companies collaborated to evaluate Mirati’s adagrasib (KRASG12C inhibitor) + Sanofi’s SAR442720 (SHP2 inhibitor) in P-I/II dose-escalation & expansion study in patients with previously-treated NSCLC & KRASG12C mutations
- Adagrasib & SAR442720 demonstrated an anti-tumor activity in pre-clinical models & both have complementary MoA
- Sanofi will be responsible for sponsoring & operating the P-I/II study & both companies will share the cost of the study. Additionally, Adagrasib is being evaluated as monothx. and in combination with other anti-cancer therapies in patients with advanced KRASG12C-mutated solid tumors, including NSCLC, colorectal cancer & pancreatic cancer
Click here to read full press release/ article | Ref: PR Newswire | Image: Trading View
The post Sanofi Signs a Non-Exclusive Clinical Collaboration Agreement with Mirati to Evaluate Adagrasib + SAR442720 (RMC-4630) in P-I/II Study for KRAS G12C-Mutated Lung Cancer first appeared on PharmaShots.
